Get the Stockscreener App
16.48
1.67%
-0.28
After Hours:
16.50
0.02
+0.12%
Mediwound Ltd stock is traded at $16.48, with a volume of 26,483.
It is down -1.67% in the last 24 hours and down -4.24% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$16.76
Open:
$16.81
24h Volume:
26,483
Relative Volume:
0.60
Market Cap:
$177.82M
Revenue:
$19.85M
Net Income/Loss:
$-12.75M
P/E Ratio:
-6.7819
EPS:
-2.43
Net Cash Flow:
$-21.94M
1W Performance:
+3.00%
1M Performance:
-4.24%
6M Performance:
-6.42%
1Y Performance:
+89.43%
1-Day Range:
$16.40
$16.81
1-Week Range:
$15.53
$16.85
52-Week Range:
$8.41
$24.00
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MDWD | 16.48 | 177.82M | 19.85M | -12.75M | -21.94M | -2.43 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
MediWound Ltd.'s (NASDAQ:MDWD) institutional investors lost 10% last week but have benefitted from longer-term gains - Simply Wall St
MediWound (MDWD) to Release Earnings on Tuesday - MarketBeat
MediWound to Discuss New Share Incentive Plan - TipRanks
MediWound to Report Third Quarter 2024 Financial Results - GlobeNewswire
MediWound Q3 2024 Earnings Call Scheduled for November 26: What to Expect | MDWD Stock News - StockTitan
99,994 Shares in MediWound Ltd. (NASDAQ:MDWD) Bought by ARK Investment Management LLC - MarketBeat
MediWound Ltd. (NASDAQ:MDWD) is Rosalind Advisors Inc.'s 5th Largest Position - MarketBeat
MediWound (STU:M8W) Financial Strength : 6 (As of Jun. 2024) - GuruFocus.com
How the (MDWD) price action is used to our Advantage - Stock Traders Daily
MediWound Is A Healthy Investment (NASDAQ:MDWD) - Seeking Alpha
MediWound's (NASDAQ:MDWD) investors will be pleased with their stellar 125% return over the last year - Yahoo Finance UK
Rosalind Advisors, Inc. Increases Stake in MediWound Ltd - Yahoo Finance
(MDWD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
MediWound (NASDAQ:MDWD) Rating Reiterated by HC Wainwright - Defense World
Trading (MDWD) With Integrated Risk Controls - Stock Traders Daily
MediWound shares maintain buy rating on new study plans - Investing.com India
MediWound shares maintain buy rating on new study plans By Investing.com - Investing.com South Africa
MediWound (NASDAQ:MDWD) Earns Buy Rating from HC Wainwright - MarketBeat
MediWound advances EscharEx in Phase II VLU study By Investing.com - Investing.com Australia
MediWound advances EscharEx in Phase II VLU study - Investing.com India
MediWound Announces Phase II Head-to-Head Study Evaluating - GlobeNewswire
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
(MDWD) On The My Stocks Page - Stock Traders Daily
Rhumbline Advisers Purchases Shares of 8,440 MediWound Ltd. (NASDAQ:MDWD) - Defense World
Objective long/short (MDWD) Report - Stock Traders Daily
TD Cowen maintains Buy rating on MediWound shares with no price target change - Investing.com
MediWound (NASDAQ:MDWD) Stock Price Crosses Below 200-Day Moving Average of $16.99 - MarketBeat
(MDWD) Long Term Investment Analysis - Stock Traders Daily
MediWound (NASDAQ:MDWD) Shares Cross Above 50 Day Moving Average of $18.20 - MarketBeat
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Critical Comparison: MediWound (NASDAQ:MDWD) versus Jinhua Marine Biological (OTCMKTS:JNMB) - Defense World
MediWound Ltd.'s (NASDAQ:MDWD) top owners are retail investors with 38% stake, while 28% is held by institutions - Yahoo Finance
MDWDMediWound Ltd. Latest Stock News & Market Updates - StockTitan
MediWound Ltd. Forecasted to Post Q3 2024 Earnings of ($0.49) Per Share (NASDAQ:MDWD) - MarketBeat
Brokers Set Expectations for MediWound Ltd.’s Q3 2024 Earnings (NASDAQ:MDWD) - Defense World
MediWound (FRA:M8W) Median PS Value : €30.03 (As of Aug. 24, 2024) - GuruFocus.com
MDWD (MediWound) Free Cash Flow : $-22.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
HC Wainwright Reiterates Buy Rating for MediWound (NASDAQ:MDWD) - Defense World
MediWound Ltd. (NASDAQ:MDWD) Forecasted to Earn FY2027 Earnings of $1.28 Per Share - Defense World
Equities Analysts Offer Predictions for MediWound Ltd.'s FY2027 Earnings (NASDAQ:MDWD) - MarketBeat
MediWound and Vericel win FDA paediatric label expansion for NexoBrid - Medical Device Network
MediWound shares hold Buy rating with steady target on expansion By Investing.com - Investing.com Australia
MediWound Second Quarter 2024 Earnings: EPS Misses Expectations - Simply Wall St
MediWound Announces U.S. Food and Drug Administration - GlobeNewswire
Vericel, MediWound climb on FDA's expanded approval for skin treatment - XM
MediWound’s NexoBrid Gains FDA Pediatric Approval - TipRanks
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):